DEF 14A: Leap Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Leap Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 18, 2025, to elect directors, approve executive compensation, and ratify the appointment of its independent auditors.

Summary

• Leap Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for June 18, 2025, at 11:30 a.m. Eastern Time.
• The meeting will be held virtually via the Internet.
• Stockholders of record as of April 30, 2025, are entitled to vote.
• The agenda includes the election of three Class II directors (Thomas Dietz, William Li, and Patricia Martin) for terms ending in 2028.
• Stockholders will also vote on an advisory resolution regarding executive compensation (Say-on-Pay) and the ratification of EisnerAmper LLP as the company's independent auditors for the year ending December 31, 2025.
• The company is providing access to proxy materials online, with a Notice of Internet Availability mailed to stockholders on or about May 9, 2025.
• Stockholders can vote online before the meeting, by telephone, by mail, or online during the virtual meeting.
• The Board of Directors recommends voting for the election of the director nominees, for the Say-on-Pay proposal, and for the ratification of the appointment of EisnerAmper LLP.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The Board's recommendations to vote in favor of all proposals suggest a positive outlook from management's perspective.

Positives

• The company is providing electronic access to proxy materials, reducing costs and environmental impact.
• The Board recommends voting in favor of all proposals, indicating confidence in the company's direction and management.
• The company has established corporate governance guidelines and committees to ensure proper oversight and management.

Risks

• The document contains forward-looking statements that are subject to various risks and uncertainties.
• Factors that could cause actual results to differ materially include clinical trial outcomes, market size estimations, financing and partnership opportunities, regulatory feedback, and compliance with Nasdaq listing criteria.
• The company's ability to regain compliance with the Nasdaq listing criteria is a risk factor.

Future Outlook

The document includes forward-looking statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, the size of the potential addressable market for sirexatamab, the anticipated timing for initiation or completion of clinical trials and release of clinical trial data, future clinical or preclinical product development plans, and estimations of projected cash runway.

Management Comments

• Christopher K. Mirabelli, Chairman of the Board of Directors, and Douglas E. Onsi, Chief Executive Officer and President, thank stockholders for their ongoing support of Leap Therapeutics.
• The Board believes that good corporate governance is important to ensure that the company is managed for the long-term benefit of its stockholders.

Industry Context

This announcement is a routine part of corporate governance for publicly traded companies, ensuring shareholders have the opportunity to participate in key decisions.

Comparison to Industry Standards

• The proxy statement adheres to SEC regulations and Nasdaq listing rules, which are standard for publicly traded companies.
• The virtual format of the annual meeting is becoming increasingly common, aligning with industry trends towards greater accessibility and cost-effectiveness.
• The director compensation and executive compensation disclosures are consistent with industry practices for biotechnology companies of similar size and stage of development.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• The outcome of the votes on director elections and executive compensation can influence the company's strategic direction and management effectiveness.

Next Steps

• Stockholders are encouraged to review the proxy materials and vote on the proposals.
• The company will report the voting results in a Current Report on Form 8-K within four business days following the adjournment of the Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, EisnerAmper, Auditor Ratification, Corporate Governance, Leap Therapeutics